Noveome Biotherapeutics
↗Pittsburgh, Pennsylvania, USA
Noveome Biotherapeutics (formerly Stemnion) is a clinical-stage biopharmaceutical company focused on developing novel biologics for the promotion and restoration of cellular integrity of inflamed or damaged tissues. The company's lead product candidate, ST266, is a first-of-its-kind, multi-targeted secretome containing hundreds of biologically active proteins and other factors crucial to neuroprotection, inflammation modulation, cell recovery, and healing. ST266 is produced by collecting the secretome from a proprietary population of amnion-derived epithelial cells sourced from donated full-term placentas, leveraging the remarkable healing and anti-scarring properties observed in fetal surgery. The company is advancing ST266 across multiple therapeutic areas including ophthalmology, neurology, dermatology, and rare pediatric diseases with significant unmet medical needs.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:Regenerative Medicine and Cell Therapy
SIZE & FINANCIALS
Employees:1-50
Founded:2000
Ownership:private
Status:operating
FUNDING
Stage:Series E
Total Raised:$170M
Investors:MAK Capital, Lancet Capital, Miraki Innovation, Kleiner Perkins, Polaris Partners, Commonwealth of Pennsylvania, Genoa Ventures, U.S. Department of Defense, Allegheny County
PIPELINE
Stage:Phase 1-2
Lead Drug Stage:Phase 1-2 (Necrotizing Enterocolitis), Phase 2 completed (Persistent Corneal Epithelial Defects)
Modalities:Secretome (cell-free biologic), Regenerative therapy
Active Trials:13
Trial Phases:Phase 1: 3 | Phase 2: 2
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:SipNose, Ltd.: Commercial license for intranasal Cribriform Targeted Device (CT6) to deliver ST266 to central nervous system (CNS) - ongoing collaboration since 2015, Walter Reed Army Institute of Research: Investigation of intranasally-delivered ST266 for Traumatic Brain Injury treatment (announced February 2021), Singota Solutions: Manufacturing support for ST266 therapy development
COMPETITION
Position:Emerging
Competitors:NGM Biopharmaceuticals, Aerie Pharmaceuticals, Animal Cell Therapies, Vitatex, Hemarina, Precision Biologics, Eloxx Pharmaceuticals, Soligenix +4 more
LEADERSHIP
Key Executives:
Christopher J. P. Velis - Chief Executive Officer
Maria Weber - Chief Financial Officer
Larry Brown - Chief Scientific Officer and Executive Vice President
Patrick T. Welch - Board Member
Scientific Founders:George L. Sing, William Golden, Lancet Capital (founding investor/collaborator)
Board Members:Christopher J. P. Velis (CEO/Board), Patrick T. Welch (experienced pharma executive), Dr. Robert Langer (MIT Institute Professor, 10+ years on board), Dr. Kevin Poropatich (Director, Center for Military Medicine Research, University of Pittsburgh), Eric Keller, J.D. (Co-Founder and CSO of Levation Pharma and Optigo Biotherapeutics), Houman D. Hemmati, M.D., Ph.D. (CMO, Vyluma), MAK Capital representative (as investor)
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Noveome Biotherapeutics. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.